Leukemia Lymphocytic Chronic B-Cell Clinical Trial
Official title:
A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND ACTIVITY OF CC-292 IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA
| Verified date | December 2019 |
| Source | Celgene |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 and lenalidomide in subjects with Chronic Lymphocytic Leukemia (CLL).
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | January 23, 2019 |
| Est. primary completion date | January 23, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Male and female subjects 18 years of age and older at the time of signing the informed consent document (ICD). - Body weight at least 50 kg. - Must have a documented diagnosis of CLL/SLL (International Workshop on Chronic Lymphocytic Leukemia IWCLL Guidelines - Hallek 2008) by investigator assessment. - Have failed at least 1 previous treatments for CLL/SLL, and have relapsed and/or refractory disease following last prior treatment defined as CLL/SLL that does not achieve at least a partial response (PR) to therapy or that progresses within 6 months of treatment. - Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or less. - Life expectancy of at least 3 months from time of signing ICD. - Females of childbearing potential (FCBP) must have a negative medically supervised pregnancy test prior to starting study therapy and agree to ongoing pregnancy testing during and after end of study therapy; commit to continued abstinence from heterosexual intercourse or agree to use, comply with two effective methods of contraception without interruption, 28 days prior to starting study drug, during study therapy, and for 28 days after discontinuation of study therapy. - Male subjects must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy, throughout study drug therapy and dose interruption, and for 28 days after end of study therapy; agree to not donate semen or sperm during study drug therapy and for 28 days after end of study drug therapy. - All subjects must understand that lenalidomide could have a potential teratogenic risk, agree to abstain from donating blood with taking lenalidomide therapy and following discontinuation of study drug therapy; have an echocardiogram (ECG) or multigated acquisition (MUGA) scan of the heart demonstrating left ventricular ejection fraction (LVEF) at least 50% or the institution's lower limit of normal; have recovered from adverse, toxic effects of prior therapies to equal to or less than 1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.03 except for alopecia and peripheral neuropathy. Exclusion Criteria: - Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. - Autologous stem cell transplant within 3 months prior to the time of signature on the ICD Informed Consent Document. - Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring parenteral antibiotics; uncontrolled diabetes mellitus; chronic symptomatic congestive heart failure; unstable angina pectoris, angioplasty, stenting, or myocardial infarctions within 6 months prior to the time of signature on the ICD; clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia. Subjects with controlled atrial fibrillation that is asymptomatic are eligible. - Pregnant or lactating females. - Prior history of malignancies, unless the subject has been free of the disease for 5 years or more prior to the time of signature on the ICD. Exceptions to the 5 years or more time limit include history of basal cell carcinoma of the skin; squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; carcinoma in situ of the bladder; incidental histologic finding of prostate cancer (Tumor/Nodes/Metastasis [TNM] stage of T1a or T1b). - Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV). - Known seropositivity for hepatitis C virus (HCV); hepatitis B virus (HBV). - Subjects who are at a high risk for a thromboembolic event and are not willing/able to take venous thromboembolic event (VTE) prophylaxis. - Any of the following laboratory abnormalities: 1. Absolute Neutrophil Count (ANC) = 1,000 cells/mm3 (1.0 x 109/L) 2. Platelet count = 50,000/mm3 (50 x 109/L) unless secondary to bone marrow involvement by recent bone marrow aspiration and bone marrow biopsy 3. Serum Aspartate Transaminase/Serum Glutamic-Oxaloacetic Transaminase (AST/SGOT) or Alanine Transaminase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) > 3.0 x upper limit of normal (ULN) or > 5.0 x ULN in cases of documented liver involvement 4. Serum bilirubin > 1.5 x ULN or > 3.0 x ULN in cases of Gilbert's Syndrome and documented liver involvement by lymphoma; 5. Calculated creatinine clearance using the Cockcroft-Gault formula (Cockcroft,1976) 6. Corrected QT interval (QTc) prolongation (defined as a QTc > 450 msec for males and > 470 msec for females [Fridericia's correction]) or other clinically significant ECG abnormalities as assessed by the investigator. - Chemotherapy, radiotherapy, investigational anticancer therapy or major surgery within 28 days of Day 1 dosing. - Use of systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day within 3 weeks prior to study drug dosing. - Concomitant use of medicines known to cause QT prolongation or torsades de pointes. - Chronic use of H2 antagonists or proton pump inhibitors or their use within 7 days of first dose. - Gastrointestinal abnormalities including the inability to take oral medication, requiring intravenous alimentation, or prior surgical procedure affecting absorption. - Prior treatment with Btk (Bruton's tyrosine kinase) inhibitors. - Any live vaccinations within 3 weeks from first dose. - History of hypersensitivity to immunomodulatory drugs (IMiDs) (eg, lenalidomide, thalidomide, pomalidomide). - Disease transformation (ie, Richter's Syndrome [lymphomas] or prolymphocytic leukemia). - Patients with uncontrolled hyper or hypothyroidism. |
| Country | Name | City | State |
|---|---|---|---|
| Austria | Universitatsklinik fur Innere Medizin | Innsbruck | |
| Austria | AKh Linz | Linz | |
| Austria | Universitatsklinik der PMU | Salzburg | |
| Austria | Allgemeines Krankenhaus Wien | Wien | |
| Austria | Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie | Wien | |
| United States | Hackensack University Medical Center | Hackensack | New Jersey |
| United States | MD Anderson Cancer Center | Houston | Texas |
| United States | Clearview Cancer Institute Oncology Specialties, P.C | Huntsville | Alabama |
| United States | Horizon Oncology Center | Lafayette | Indiana |
| United States | The West Clinic | Memphis | Tennessee |
| United States | Mount Sinai School of Medicine | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Celgene |
United States, Austria,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Adverse Events | Number of participants with adverse events | Up to 5 years | |
| Secondary | Percentage of Participants Who Have Received Some Form of Response | Response rate is defined as the percentage of participants who have achieved some form of response including: a Complete Response (CR), a CR with incomplete bone marrow recovery, a Nodular Partial Response (PR), a Nodal PR or a PR with lymphoctyosis) based on the International Workshop for Chronic Lymphocytic Leukemia and lymphoma guidelines (IWCLL). | Up to 2 years | |
| Secondary | PK-Cmax | Maximum observed plasma concentration | Up to 15 days | |
| Secondary | PK-Tmax | Time to maximum observed plasma concentration | Up to 15 days | |
| Secondary | PK-?z | Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear plasma concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration | Up to 15 days | |
| Secondary | PK-t1/2 | Estimate of the terminal elimination half-life in plasma | Up to 15 days | |
| Secondary | PK-AUC (0-t) | Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point | Up to 15 days | |
| Secondary | PK-AUC0-8 | Area under the plasma concentration time curve from time zero extrapolated to infinity. | Up to 15 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01744626 -
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
|
Phase 1 |